IDEA Pharma Revenue and Competitors
Estimated Revenue & Valuation
- IDEA Pharma's estimated annual revenue is currently $9M per year.
- IDEA Pharma's estimated revenue per employee is $201,000
Employee Data
- IDEA Pharma has 45 Employees.
- IDEA Pharma grew their employee count by -6% last year.
IDEA Pharma's People
Name | Title | Email/Phone |
---|---|---|
1 | CEO | Reveal Email/Phone |
2 | Head IDEA Pharma US | Reveal Email/Phone |
3 | Finance Director | Reveal Email/Phone |
4 | Chief Medical Officer | Reveal Email/Phone |
5 | Administrative Assistant | Reveal Email/Phone |
6 | Principal, Client Relations | Reveal Email/Phone |
7 | IDEAtor (Strategy Consultant) | Reveal Email/Phone |
8 | Senior Account Manager | Reveal Email/Phone |
9 | Senior Account Director | Reveal Email/Phone |
10 | IDEAtor / Head London Office | Reveal Email/Phone |
IDEA Pharma Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $46.2M | 230 | 5% | N/A | N/A |
#2 | $43.8M | 218 | 21% | N/A | N/A |
#3 | $57.1M | 284 | 26% | N/A | N/A |
#4 | $24.5M | 122 | 3% | N/A | N/A |
#5 | $52.9M | 263 | 13% | N/A | N/A |
#6 | $24.7M | 123 | 13% | N/A | N/A |
#7 | $1.8M | 18 | 0% | $114.3M | N/A |
#8 | $7.2M | 36 | -20% | N/A | N/A |
#9 | $13.7M | 68 | -7% | N/A | N/A |
#10 | $7.6M | 39 | -13% | $123.9M | N/A |
What Is IDEA Pharma?
Who? Pharma's experts in path-to-market strategy, positioning and applied innovation. What? IDEA Pharma is a Path-To-Market Strategy practice. Applied Design Thinking in early phase. Where? Offices in UK, Basel, San Francisco, New York City, with global clients in those countries plus Denmark, Germany, and France. Why? Choosing a path to market successfully is a discipline, and like any discipline, it is best performed by specialists. Pharma works with IDEA to develop options for the 'best' path to market: clinically and commercially. IDEA supported 2 of 2017's 5 biggest launches, 3 of 2016's top 10, and 4 of 2015's top 10. No other company comes close. IDEA has been lucky enough to work with some of the best product teams in the industry, and we will only engage if we believe in the client team. It's a philosophy that has ensured we love what we do, and that we can make the kind of difference that matters,. How? Areas of industry leadership include: • Strategic Positioning • Portfolio/ disease area Strategy • Value Proposition • Scenario planning, Strategy pressure test • Communication Strategy The path-to-market for a medicine is never obvious, so we develop design options: IDEAs that meet every hurdle: clinical, regulatory, and the important commercial hurdles (market access, reimbursement, competitor differentiation…). Clearing any one is relatively easy; clearing all of them is hard. A thousand things can influence the trajectory of a product: choice of indication, patient population, patient profile, line of therapy, trial endpoints, and many more. Products are the result of design decisions. When design is valued, great things happen. IDEAtion: generation, evaluation, iteration and decision-making for path-to-market options. Faster-to-market options, higher value, lower technical risk, greater probability of commercial success
keywords:N/AN/A
Total Funding
45
Number of Employees
$9M
Revenue (est)
-6%
Employee Growth %
N/A
Valuation
N/A
Accelerator
IDEA Pharma News
Documents show close talks between Canadian government and pharma over ... for Covid vaccines, nearly 18 months after the idea was proposed.
"On behalf of the Board and Lantern Pharma, I would like to thank Les ... Lantern through its journey from a novel idea to a well-funded,...
IDEA Pharma, a life sciences strategy firm which advises biotech and pharmaceutical companies on the best pathways to true innovation in...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $5.8M | 64 | 0% | N/A |
#2 | $26.5M | 87 | N/A | N/A |
#3 | $27.3M | 111 | 31% | N/A |
#4 | $77.2M | 242 | 9% | N/A |
#5 | $15M | 321 | 9% | N/A |